Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
INOV

Inovalon

$15.42

0.49 (3.28%)

05:34
02/21/19
02/21
05:34
02/21/19
05:34
Recommendations
Inovalon analyst commentary at Piper Jaffray »

Piper 'not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

INOV

Inovalon

$15.42

0.49 (3.28%)

16:24
02/20/19
02/20
16:24
02/20/19
16:24
Earnings
Inovalon backs FY19 EPS view 41c-47c, consensus 42c »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

INOV

Inovalon

$15.42

0.49 (3.28%)

16:21
02/20/19
02/20
16:21
02/20/19
16:21
Earnings
Inovalon reports Q4 EPS 5c, consensus 9c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

INOV

Inovalon

$15.14

0.92 (6.47%)

12:20
02/15/19
02/15
12:20
02/15/19
12:20
Hot Stocks
Neuberger Berman reports 5.1% passive stake in Inovalon »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

Over a quarter ago
INOV

Inovalon

$14.43

0.1 (0.70%)

08:00
01/17/19
01/17
08:00
01/17/19
08:00
Hot Stocks
Inovalon announces multi-year expansion of APWUHP contract »

Inovalon announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$86.30

1.38 (1.63%)

, NVS

Novartis

$84.60

-1.28 (-1.49%)

10:15
01/07/19
01/07
10:15
01/07/19
10:15
Conference/Events
JPMorgan to hold a conference »

37th Annual Healthcare…

CELG

Celgene

$86.30

1.38 (1.63%)

NVS

Novartis

$84.60

-1.28 (-1.49%)

DXCM

DexCom

$127.22

10.98 (9.45%)

MOH

Molina Healthcare

$107.89

-1.82 (-1.66%)

BMRN

BioMarin

$89.63

2.575 (2.96%)

PFE

Pfizer

$42.99

(0.00%)

CAH

Cardinal Health

$44.93

0.03 (0.07%)

GILD

Gilead

$67.82

-0.45 (-0.66%)

VAR

Varian Medical

$119.16

0.4 (0.34%)

BAX

Baxter

$66.46

-0.01 (-0.02%)

ABC

AmerisourceBergen

$74.22

-0.075 (-0.10%)

EW

Edwards Lifesciences

$148.94

0.25 (0.17%)

ATRX

Atrix Laboratories

$0.00

(0.00%)

INCY

Incyte

$74.29

2.02 (2.80%)

JNJ

Johnson & Johnson

$126.99

-0.81 (-0.63%)

NBIX

Neurocrine

$79.49

4.73 (6.33%)

DVA

DaVita

$53.92

-0.09 (-0.17%)

INOV

Inovalon

$13.69

-0.16 (-1.16%)

SIEGY

Siemens

$0.00

(0.00%)

MRK

Merck

$75.87

-0.39 (-0.51%)

BIIB

Biogen

$320.36

2.17 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 07

    Jan

  • 07

    Jan

  • 07

    Jan

  • 07

    Jan

  • 11

    Jan

  • 14

    Jan

  • 22

    Jan

  • 23

    Jan

  • 27

    Jan

  • 28

    Jan

  • 28

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 14

    Feb

  • 16

    Feb

  • 18

    Feb

  • 21

    Feb

  • 11

    Apr

  • 18

    May

  • 24

    May

CELG

Celgene

$84.92

4.4 (5.46%)

, NVS

Novartis

$85.88

1.1 (1.30%)

08:47
01/07/19
01/07
08:47
01/07/19
08:47
Conference/Events
JPMorgan to hold a conference »

37th Annual Healthcare…

CELG

Celgene

$84.92

4.4 (5.46%)

NVS

Novartis

$85.88

1.1 (1.30%)

DXCM

DexCom

$116.24

3.83 (3.41%)

MOH

Molina Healthcare

$109.71

3.69 (3.48%)

BMRN

BioMarin

$87.06

2.935 (3.49%)

PFE

Pfizer

$42.99

0.95 (2.26%)

CAH

Cardinal Health

$44.90

0.75 (1.70%)

GILD

Gilead

$68.27

3.08 (4.72%)

VAR

Varian Medical

$118.76

8.93 (8.13%)

BAX

Baxter

$66.47

2.04 (3.17%)

ABC

AmerisourceBergen

$74.30

0.985 (1.34%)

EW

Edwards Lifesciences

$148.69

5.27 (3.67%)

ATRX

Atrix Laboratories

$0.00

(0.00%)

INCY

Incyte

$72.27

4.25 (6.25%)

JNJ

Johnson & Johnson

$127.80

1.99 (1.58%)

NBIX

Neurocrine

$74.76

5.32 (7.66%)

DVA

DaVita

$54.01

3.04 (5.96%)

INOV

Inovalon

$13.85

0.35 (2.59%)

SIEGY

Siemens

$0.00

(0.00%)

MRK

Merck

$76.26

2.22 (3.00%)

BIIB

Biogen

$318.19

11.62 (3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 07

    Jan

  • 11

    Jan

  • 14

    Jan

  • 22

    Jan

  • 23

    Jan

  • 27

    Jan

  • 28

    Jan

  • 28

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 14

    Feb

  • 16

    Feb

  • 18

    Feb

  • 21

    Feb

  • 11

    Apr

  • 18

    May

  • 24

    May

INOV

Inovalon

$13.04

0.36 (2.84%)

07:38
12/20/18
12/20
07:38
12/20/18
07:38
Upgrade
Inovalon rating change  »

Inovalon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INOV

Inovalon

$13.04

0.36 (2.84%)

05:40
12/20/18
12/20
05:40
12/20/18
05:40
Upgrade
Inovalon rating change at Morgan Stanley »

Inovalon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INOV

Inovalon

$12.58

0.14 (1.13%)

05:30
12/13/18
12/13
05:30
12/13/18
05:30
Recommendations
Inovalon analyst commentary at Piper Jaffray »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.